A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro

Autor:	Marcus Schmidt, Christoph Thomssen, Stefan Fuxius, Tanja Fehm, Martina Seehase, Thomas Decker, Ingolf Juhasz-Böss, Nadia Harbeck, Lukas Schollenberger, Christian Ruckes, Volker Möbus
Rok vydání:	2017
Předmět:	Oncology medicine.medical_specialty business.industry Endocrine therapy Phases of clinical research General Medicine Vinorelbine medicine.disease Breast cancer Hormone receptor Internal medicine medicine Surgery First line chemotherapy business Human Epidermal Growth Factor Receptor 2 medicine.drug
Zdroj:	The Breast. 36:S51
ISSN:	0960-9776
DOI:	10.1016/s0960-9776(17)30701-4
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::57f070c347bb6dfcda1e4653c7517b7f https://doi.org/10.1016/s0960-9776(17)30701-4 Zobrazit plný text záznamu Full Text from ScienceDirect